This page shows the latest Ongentys news and features for those working in and with pharma, biotech and healthcare.
The COMT inhibitor was approved in Europe as Ongentys last June as an adjunct to Parkinson's disease treatment, and Neurocrine is hoping to meet with the FDA to see what
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Bial says its drug will be
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
execute a successful virtual launch if it is going to compete with drugs such as Inbrija (Acorda Therapeutics), Nourianz (Kyowa Kirin), and Ongentys (Neurocrine Biosciences).
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...